Neovacs

Neovacs Quick Ratio

The Quick Ratio (Acid Test) of Neovacs (ALNEV.PA) as of Oct 17, 2026 is 0.64. In the previous year, Quick Ratio (Acid Test) was 1.03 — a change of -37.22% (lower).

Quick Ratio

0.64

YoY

-37.22%

Last updated:

Quick Ratio (Acid Test) of Neovacs is 2024 0.64 . Quick Ratio (Acid Test) of Neovacs was 2023 1.03 . It decreases by -37.22% lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neovacs Stock analysis

What does Neovacs do? Neovacs SA is a biotechnology company headquartered in Paris, France, specializing in the development of active immunotherapies for autoimmune, inflammatory, and cancerous diseases. The firm employs 24 full-time staff and operates in France and the United States. Neovacs focuses on creating Kinoids, which are drug candidates designed to treat disease by inducing an antibody response in the patient. Its product portfolio includes TNF-Kinoids, IFN-Kinoids, and VEGF-Kinoids. The company specifically targets conditions such as Crohn’s disease, rheumatoid arthritis, and lupus. In May 2016, Neovacs entered into a joint venture agreement with Stellar Biotechnologies Inc to establish Neostell, in which Neovacs holds a 70% stake. The company listed on the market on April 15, 2010. Neovacs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neovacs stock

Quick Ratio (Acid Test) of Neovacs is 0.64 in 2024.

Quick Ratio (Acid Test) of Neovacs changed from 1.03 to 0.64, representing a -37.22% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Quick Ratio (Acid Test) Neovacs since 2006 – with annual values, charts, and detailed analysis.

The Quick Ratio measures liquidity by comparing liquid assets to current liabilities, excluding inventory. It is a more conservative measure than the current ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Quick Ratio (Acid Test)'s Neovacs with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Neovacs

All Key Metrics — Neovacs